BiotechTube
Home/Vivazome/David Haylock
DH

David Haylock

Chief Scientific Officer

Vivazome

Therapeutic Areas

NeurologyNeurodegeneration

Vivazome Pipeline

DrugIndicationPhase
VivaZome TBI TherapyTraumatic Brain Injury (including Post‑Traumatic Epilepsy)Preclinical
VivaZome Stroke TherapyAcute and Chronic StrokePreclinical
VivaZome Tauopathy TherapyNeurodegenerative diseases (tauopathies, dementia)Preclinical

Leadership Team at Vivazome

AF
Anthony Filippis
Non‑Executive Director
CN
Craig Newton
Non‑Executive Director
XS
Xenia Sango
Chief Executive Officer & Managing Director
View full Vivazome profile